small molecule

AGAMREE

VAMOROLONE

Loss of exclusivityJuly 2040latest FDA-listed patent expiry

CompanyCatalyst →View the full company profile on CliffBio

Drug detail

Brand name	AGAMREE
Active ingredient	VAMOROLONE
Strength	40MG/ML
Dosage form	SUSPENSION
Route	ORAL
Modality	Small molecule
FDA approval	October 2023
Marketing status	RX

Listed patents

Patent	Expires	Type
11382922	July 2040	substance, product
11471471	March 2040	use U-3747
12201639	March 2040	substance, product
11690853	March 2033	use U-3747
10857161	May 2029	product
8334279	May 2029	use U-3747
11833159	May 2029	product

Regulatory exclusivity

Code	Expires
ODE-450	October 2030
NCE	October 2028

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

Drug detail

Listed patents

Regulatory exclusivity

More from Catalyst